<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of actinomycosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of actinomycosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of actinomycosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Itzhak Brook, MD, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen B Calderwood, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 23, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2311501032">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of actinomycosis often entails prolonged courses of antimicrobials. Surgical intervention may also be necessary in more complicated cases, such as infection in critical spaces (eg, epidural infections, brain abscesses), patients with massive hemoptysis, or when extensive abscesses and fistulous tracts are present.
        </p>
        <p>
         The treatment of actinomycosis will be discussed here. The clinical manifestations and diagnosis of actinomycosis are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/3411.html" rel="external">
          "Cervicofacial actinomycosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2691.html" rel="external">
          "Abdominal actinomycosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3185313902">
         <span class="h1">
          ANTIMICROBIAL THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H1145233073">
         <span class="h2">
          Monomicrobial infections
         </span>
        </p>
        <p class="headingAnchor" id="H1868180873">
         <span class="h3">
          Preferred regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         We generally suggest high-dose penicillin for actinomycosis [
         <a href="#rid1">
          1-3
         </a>
         ]. Reasonable alternatives include
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         and
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         . The route of administration depends on the severity of infection:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe or extensive actinomycosis
         </strong>
         – Severe, extensive infection is often invasive and associated with significant purulence or fistulous tracts, and often occurs in patients with significant underlying comorbidities. For severe infection, we recommend an initial course of intravenous
         <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">
          penicillin G
         </a>
         (10 to 20 million units daily in divided doses every four to six hours) [
         <a href="#rid4">
          4-6
         </a>
         ]. In the outpatient setting, administering penicillin G as a continuous infusion may make dosing less cumbersome.
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          Ceftriaxone
         </a>
         (1 to 2 g every 24 hours) is a reasonable alternative that can also be more easily administered for treatment in the outpatient setting [
         <a href="#rid7">
          7
         </a>
         ]. Surgery is also warranted in certain severe cases. (See
         <a class="local">
          'Surgical management in select cases'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Initial parenteral therapy is typically given for four to six weeks. Switching from intravenous to oral therapy is usually possible after there is significant improvement in the patient's condition, which typically happens within this time frame. The parenteral regimen is followed by oral
         <a class="drug drug_general" data-topicid="9751" href="/z/d/drug information/9751.html" rel="external">
          penicillin V
         </a>
         (2 to 4 g per day, divided into four daily doses). Oral
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         is probably equally efficacious [
         <a href="#rid4">
          4
         </a>
         ]. Data informing the optimal dose of amoxicillin are limited, but we generally use 1.5 to 3 g per day, divided into three or four daily doses. For all the antibiotic regimens, we use a dose at the higher end of the range for more serious infections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild actinomycosis (eg, limited oral disease)
         </strong>
         – Initial oral antimicrobial therapy is appropriate for mild cases. We recommend oral
         <a class="drug drug_general" data-topicid="9751" href="/z/d/drug information/9751.html" rel="external">
          penicillin V
         </a>
         (2 to 4 g per day, divided into four daily doses). Oral
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         (1.5 to 3 g per day, divided into three or four daily doses) is another option. In cases where copathogens are suspected, oral
         <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">
          amoxicillin-clavulanate
         </a>
         can be used [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="local">
          'Polymicrobial infections'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Oral antimicrobials are typically administered for a prolonged course for both severe and mild infection; duration is discussed in detail elsewhere. (See
         <a class="local">
          'Duration of antimicrobial therapy'
         </a>
         below.)
        </p>
        <p>
         No randomized controlled studies have evaluated antimicrobial regimens for actinomycosis. The preference for penicillin is based on in vitro antimicrobial susceptibility testing and small case series where high-dose penicillin was used successfully [
         <a href="#rid3">
          3,4,9-11
         </a>
         ]. Furthermore, acquired resistance to
         <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">
          penicillin G
         </a>
         by
         <em>
          Actinomyces
         </em>
         during prolonged therapy is rare. Penicillin is given in high doses because of the need to obtain effective concentration in the infected tissues [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3617539741">
         <span class="h3">
          Alternatives for penicillin-allergic patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acceptable alternatives to penicillin include
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         , macrolides (
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         ), and carbapenems. These agents can be used in those who cannot tolerate penicillin [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         For penicillin-allergic patients, the approach to regimen selection depends on the type of allergy and the severity of disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with severe infection and a mild, non-immunoglobulin (Ig)E-mediated reaction to penicillin (eg, maculopapular rash beginning days into therapy), we generally use
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         (1 to 2 g every 24 hours) as initial therapy for four to six weeks prior to oral step-down therapy. Ceftriaxone can also be administered with a test dose procedure to patients with suspected IgE mediated reaction to penicillin (eg, urticaria, anaphylaxis). (See
         <a class="medical medical_review" href="/z/d/html/111361.html" rel="external">
          "Choice of antibiotics in penicillin-allergic hospitalized patients", section on 'Management of mild reactions WITHOUT history of features of immediate allergy (minimal risk of immediate allergy)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/111361.html" rel="external">
          "Choice of antibiotics in penicillin-allergic hospitalized patients", section on 'Management of reactions WITH features of immediate allergy (some risk)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with severe infection and an allergy that precludes
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         use (eg, serious delayed reactions to beta-lactams), we generally use
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         (100 mg every 12 hours, by mouth or intravenous).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For oral step-down therapy with severe infection and for mild infection in patients with a penicillin allergy, we generally use
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         (100 mg every 12 hours) [
         <a href="#rid5">
          5,13
         </a>
         ]. Another acceptable alternative to penicillin is
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         base 500 mg orally every six hours [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         These alternatives have in vitro activity against
         <em>
          Actinomyces
         </em>
         and have been used successfully against
         <em>
          Actinomyces
         </em>
         in limited clinical series.
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          Imipenem
         </a>
         is another potential alternative based on even more limited clinical reports [
         <a href="#rid16">
          16
         </a>
         ].
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          Ertapenem
         </a>
         is also likely to be effective and offers the advantage of once-daily dosing for outpatient parenteral therapy.
        </p>
        <p class="headingAnchor" id="H277155039">
         <span class="h3">
          Agents that should be avoided
         </span>
         <span class="headingEndMark">
          —
         </span>
         Aminoglycosides,
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         , penicillinase-resistant penicillins (eg,
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         ),
         <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">
          cephalexin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         , and antifungal drugs are not active against these organisms and should not be used for therapy [
         <a href="#rid13">
          13-15,17,18
         </a>
         ].
        </p>
        <p>
         Although
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         and fluoroquinolones have some in vitro activity against
         <em>
          Actinomyces
         </em>
         , resistance to these agents is not uncommon and since susceptibility testing is not typically available, reliable activity cannot be assumed [
         <a href="#rid17">
          17,19,20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H383372889">
         <span class="h3">
          Duration of antimicrobial therapy
         </span>
        </p>
        <p class="headingAnchor" id="H3350203203">
         <span class="h4">
          Classic actinomycosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We typically treat patients with classic
         <em>
          Actinomyces
         </em>
         syndromes (eg, cervicofacial, thoracic, or abdominal actinomycosis with fibrotic reaction, sulfur granules, or invasion of contiguous structures) for an extended period of time to prevent disease recrudescence. Treatment should generally be continued for at least one to two months after resolution of the observed infection; this usually amounts to 2 to 6 months for mild disease and 6 to 12 months for severe.
        </p>
        <p>
         Within these ranges, individualization of the duration depends on the initial burden of disease, the site of infection, success of any surgical debridement, and the clinical and radiologic response to treatment [
         <a href="#rid21">
          21,22
         </a>
         ]. Extension of the duration to 12 to 18 months may be warranted for complicated and invasive cases, immunocompromised patients, and patients with human immunodeficiency virus (HIV) infection. Shorter courses may also be appropriate, even for initially severe cases, if there has been adequate surgical resection of infected tissues, there is no bone involvement, and response to treatment is rapid. Infections that are recognized early and cause smaller and less indurated lesions have also been successfully treated with shorter durations of therapy. Close monitoring of patients is essential when shorter treatment durations are planned.
        </p>
        <p>
         Antimicrobials are typically given for a prolonged duration for classic actinomycosis because the infection has a tendency to recur, especially in thoracic infections [
         <a href="#rid23">
          23,24
         </a>
         ]. However, several case series have reported that courses of treatment &lt;6 months have been successful, especially in cervicofacial actinomycosis [
         <a href="#rid4">
          4,25-27
         </a>
         ]. Another study with 17 patients with thoracic actinomycosis reported successful outcomes with two weeks of intravenous penicillin followed by three months of penicillin orally; over half the patients received surgical intervention to distinguish malignancy from an alternative process. [
         <a href="#rid28">
          28
         </a>
         ]. Shorter courses of therapy should be used with caution in patients with thoracic disease who have not undergone surgical debridement as patients treated with antibiotics alone for less than three months may be at higher risk of recurrence [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Even shorter courses have been described in some cases, although we do not generally recommend a treatment course less than two months for classic actinomycosis given the limited data. In one report, 19 patients with cervicofacial actinomycosis were successfully treated with one to four weeks of antibiotics [
         <a href="#rid26">
          26
         </a>
         ]. Most patients had presented within seven days of the onset of symptoms and 84 percent had surgical debridement in addition to antibiotic therapy. In one case report of pelvic actinomycosis associated with an intrauterine device (IUD) that presented as a mass lesion, infection resolved after a total of six weeks of oral antibiotic therapy and IUD removal without accompanying surgical debridement [
         <a href="#rid30">
          30
         </a>
         ]. Reports of thoracic actinomycosis have also shown success of short-term treatment [
         <a href="#rid28">
          28,31
         </a>
         ]. One study with 19 patients, seven of whom had surgical resection, reported cure with a median duration of six weeks of antibiotic therapy [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H684558184">
         <span class="h4">
          Non-classic presentations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of polymicrobial infections that are not a classic actinomycosis syndrome (ie, subcutaneous drained abscess, periodontitis, isolation from the sputum in the absence of involvement of the chest wall or other contiguous structures, lack of a fibrotic reaction or sulfur granules) can be shorter than for classic actinomycosis (eg, two to six weeks). Limited dental disease, such as periapical infection can be successfully treated with 10 to 14 days of therapy [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Data informing the duration of treatment in these cases are limited, but in the absence of bulky, extending or fistulous disease, the risk of relapse with shorter courses of therapy is thought to be lower.
        </p>
        <p class="headingAnchor" id="H190957679">
         <span class="h2">
          Polymicrobial infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 75 to 95 percent of cultures in which
         <em>
          Actinomyces
         </em>
         is isolated grow other organisms. The most common coisolates are
         <em>
          Actinobacillus actinomycetemcomitans, Eikenella corrodens
         </em>
         ,
         <em>
          Fusobacterium, Bacteroides, Capnocytophaga, Staphylococcus, Streptococcus, and Enterococcus
         </em>
         spp [
         <a href="#rid1">
          1
         </a>
         ]. Concomitant pulmonary infection of tuberculosis and actinomycosis has been rarely reported [
         <a href="#rid32">
          32
         </a>
         ]. Whether treatment of co-isolates is warranted depends on the organism. When known pathogens are isolated with
         <em>
          Actinomyces
         </em>
         , they can act synergistically, and in such cases, antimicrobial coverage for these additional organisms is appropriate. Managing copathogens is particularly important in invasive infections and lower-abdominal infections, in which significant copathogens may be recovered in culture. Treatment of
         <em>
          Staphylococcus aureus,
         </em>
         <em>
          Proteus
         </em>
         , and
         <em>
          Pseudomonas
         </em>
         is always warranted.
        </p>
        <p>
         When broader therapy for coverage of copathogens is warranted, we use a combination beta-lactam plus beta-lactamase inhibitor. Examples include
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         (3.375 g intravenously every six hours) and
         <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">
          amoxicillin-clavulanate
         </a>
         (immediate release 500 mg orally every 8 hours or 875 mg orally every 12 hours). These agents offer the advantage of coverage against penicillin-resistant aerobic and anaerobic pathogens. Some copathogens can produce a beta-lactamase that can "shield"
         <em>
          Actinomyces
         </em>
         from penicillin [
         <a href="#rid5">
          5
         </a>
         ], and addition of the beta-lactamase inhibitor can overcome this. Carbapenems are a potential alternative as they are likely active against
         <em>
          Actinomyces
         </em>
         and will cover other pathogens as well. Additional coverage may be warranted in cases of resistant pathogens (eg, methicillin-resistant
         <em>
          S. aureus
         </em>
         ).
        </p>
        <p>
         The duration of treatment for copathogens (with the exception of mycobacterium) is shorter than what is needed for actinomycosis and should be dictated by the infectious syndrome; subsequent to that, continued antimicrobial therapy can be directed to
         <em>
          Actinomyces
         </em>
         alone. (See
         <a class="local">
          'Monomicrobial infections'
         </a>
         above.)
        </p>
        <p>
         Therapy does not usually need to be directed against commensal flora (ie,
         <em>
          Staphylococcus epidermidis
         </em>
         ,
         <em>
          Cutibacterium
         </em>
         [formerly
         <em>
          Propionibacterium
         </em>
         ]
         <em>
          acnes
         </em>
         ) that are recovered along with
         <em>
          Actinomyces
         </em>
         , since antimicrobial regimens effective against
         <em>
          Actinomyces
         </em>
         alone are usually curative unless foreign material is present [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H838039660">
         <span class="h1">
          SURGICAL MANAGEMENT IN SELECT CASES
         </span>
        </p>
        <p>
         The need for surgery or percutaneous intervention depends on the severity, extent, and location of disease. Surgical or percutaneous management is generally not necessary for mild infections in which there is no bony involvement, no fistulous tracts, no abscesses, and no necrotic tissue. It may be warranted in more complicated cases, such as infection in critical spaces (eg, epidural infections, intracranial abscesses [
         <a href="#rid33">
          33
         </a>
         ], hepatic abscesses [
         <a href="#rid34">
          34
         </a>
         ]), infection complicated by massive hemoptysis, or when extensive abscesses and fistulous tracts are present. The main objective of surgical management is to reduce the bulk of disease, and in some cases it is necessary to prevent life-threatening complications [
         <a href="#rid35">
          35,36
         </a>
         ]. As an example, in a report of 94 patients with pulmonary actinomycosis, half of the patients ultimately required surgery, many for cure due to refractory hemoptysis [
         <a href="#rid37">
          37
         </a>
         ]. If amenable to percutaneous drainage, abscesses can often be successfully managed this way [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         However, even in severe cases, surgical or percutaneous intervention may not be necessary if infection does not involve critical spaces (eg, cervicofacial infection at the angle of the jaw) and in such cases, the need for intervention should be individualized (eg, taking into account the risk for surgery in patients with other comorbidities). Reports of successful treatment of
         <em>
          Actinomyces
         </em>
         infections, including extensive infections, with antimicrobials alone are increasing [
         <a href="#rid29">
          29,38
         </a>
         ]. In a series of 46 patients with pulmonary actinomycosis who did not undergo surgical intervention, all 43 patients with follow-up data had documented clinical cure following intravenous antimicrobial treatment for a median of 22 days then oral antimicrobial treatment for a median of 115 days [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         If indicated, surgery (or percutaneous management) is always performed in conjunction with antimicrobial therapy; surgical management alone is rarely successful without concurrent antimicrobial therapy based on clinical experience [
         <a href="#rid1">
          1,39
         </a>
         ]. (See
         <a class="local">
          'Antimicrobial therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4028030040">
         <span class="h1">
          SPECIFIC CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2558116802">
         <span class="h2">
          IUD associated infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Actinomyces
         </em>
         may be seen as an incidental finding on Pap smear in women with intrauterine devices (IUDs). In the absence of signs or symptoms of pelvic inflammatory disease (PID), therapy for
         <em>
          Actinomyces
         </em>
         and removal of the IUD are not necessary.
        </p>
        <p>
         However, features concerning for PID in this setting suggest active infection with
         <em>
          Actinomyces
         </em>
         , which warrants IUD removal, culture, and radiographic definition of the extent of disease (eg, ultrasound). If
         <em>
          Actinomyces
         </em>
         grows on culture in this setting, targeted treatment for this pathogen is given in addition to the standard empiric PID therapy. Antimicrobial regimens for
         <em>
          Actinomyces
         </em>
         are the same as discussed above. (See
         <a class="local">
          'Antimicrobial therapy'
         </a>
         above.)
        </p>
        <p>
         If imaging suggests invasive disease (eg, abscess),
         <em>
          Actinomyces
         </em>
         -targeted treatment typically consists of several weeks of intravenous therapy followed by oral therapy until at least one to two months following clinical and radiographic resolution of disease. If imaging does not suggest invasive disease, this likely represents an early stage of IUD-associated infection and can likely be treated with a shorter course of therapy against
         <em>
          Actinomyces
         </em>
         . (See
         <a class="local">
          'Duration of antimicrobial therapy'
         </a>
         above.)
        </p>
        <p>
         Management of the IUD in the setting of
         <em>
          Actinomyces
         </em>
         is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5422.html" rel="external">
          "Intrauterine contraception: Management of side effects and complications", section on 'Actinomyces and related organisms'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3181531561">
         <span class="h2">
          Bisphosphonate and radiation-associated osteonecrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bisphosphonate and radiation-associated osteonecrosis have been associated with
         <em>
          Actinomyces
         </em>
         infection of the jaw. [
         <a href="#rid40">
          40,41
         </a>
         ]. If
         <em>
          Actinomyces
         </em>
         is isolated from a patient with this, we suggest treatment as for typical actinomycosis. (See
         <a class="local">
          'Antimicrobial therapy'
         </a>
         above.)
        </p>
        <p>
         It has been postulated that
         <em>
          Actinomyces
         </em>
         has a direct effect on bisphosphonate osteonecrosis and treatment; directed antibiotics can lessen ongoing bone destruction.
        </p>
        <p class="headingAnchor" id="H112248885">
         <span class="h2">
          Prosthetic joint infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prosthetic joint infections caused by
         <em>
          Actinomyces
         </em>
         are rare and treatment strategies are not established. In a case series of 11 patients with
         <em>
          Actinomyces
         </em>
         knee and hip prosthetic joint infections, antimicrobials were administered before a two-stage exchange of the joint in 8 (72 percent) cases and 10 (91 percent) recovered after a median follow-up duration of two years [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1542777411">
         <span class="h2">
          Bacteremia without defined disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bacteremia with
         <em>
          Actinomyces
         </em>
         species has been reported. Most cases of isolated bacteremia with
         <em>
          Actinomyces
         </em>
         (ie, without other site of evident infection) likely require no treatment but warrant close follow up, especially if risk factors are present. In one series, patients without risk factors for invasive disease (eg diabetes mellitus, local tissue trauma, recent surgery, immunosuppression) were not treated for actinomycosis and suffered no ill consequences [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         However, sepsis due to
         <em>
          Actinomyces
         </em>
         species has been reported. In one case report, a patient developed sepsis due to
         <em>
          Actinomyces neslundii
         </em>
         that originated from chronic asymptomatic periapical tooth abscesses; the patient was treated with
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         intravenously for four weeks followed by oral
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         for the next five months [
         <a href="#rid44">
          44
         </a>
         ]. In another case report, a premature newborn with
         <em>
          Actinomyces odontolyticus
         </em>
         sepsis was treated with ampicillin/amoxicillin [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4276957555">
         <span class="h1">
          FOLLOW-UP
         </span>
        </p>
        <p class="headingAnchor" id="H3941859386">
         <span class="h2">
          Monitoring treatment response
         </span>
         <span class="headingEndMark">
          —
         </span>
         The response to treatment should be carefully monitored and imaging with computed tomography or magnetic resonance imaging may be necessary to ensure resolution. PET scan has also been used to follow resolution of disease during a course of treatment but needs to be used judiciously as findings may be misleading [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Imaging studies are obtained throughout treatment (eg, after the first four weeks and then every six weeks or as indicated by the patient's improvement) and prior to conclusion of therapy. Erythrocyte sedimentation rate and C-reactive protein levels are usually elevated but are not reliable for using as a follow-up parameter.
        </p>
        <p class="headingAnchor" id="H2805727918">
         <span class="h2">
          Treatment failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         If there is an incomplete response to antimicrobials alone, patients who did not initially undergo surgical debridement may ultimately require surgery [
         <a href="#rid36">
          36,47-49
         </a>
         ]. If there is a failure of therapy, a change from penicillin to another antibiotic is warranted to cover copathogens that may be present; additionally, the need for surgical debridement should be assessed [
         <a href="#rid4">
          4,21,22,25-28,30,31
         </a>
         ]. Additional empiric coverage for other potential aerobic and anaerobic copathogens may be needed in those who fail penicillin therapy especially if adequate cultures (eg, for anaerobic bacteria) were not obtained. (See
         <a class="local">
          'Polymicrobial infections'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2311501062">
         <span class="h1">
          OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of antimicrobials has greatly improved the prognosis for all forms of actinomycosis. Cure rates are high and neither deformity nor death is common [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2311501070">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preferred regimens
         </strong>
         − We suggest high-dose penicillin for antimicrobial treatment of actinomycosis (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial parenteral therapy for severe infections
         </strong>
         − Severe or extensive actinomycosis is initially treated with parenteral therapy (
         <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">
          penicillin G
         </a>
         10 to 20 million units daily in divided doses). For patients who cannot take penicillin,
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         is an alternative. (See
         <a class="local">
          'Preferred regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild infections and oral step-down therapy
         </strong>
         − Oral penicillin (2 to 4 g daily in divided doses) is used for step-down therapy and for mild infections (eg, without significant suppuration or fistulous tracts).
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          Amoxicillin
         </a>
         is an alternative. (See
         <a class="local">
          'Preferred regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternatives for penicillin- and cephalosporin-allergic patients
         </strong>
         − For patients who cannot use penicillin,
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         , we suggest
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         as a non-beta-lactam alternative (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Other alternatives include macrolides and carbapenems. (See
         <a class="local">
          'Alternatives for penicillin-allergic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of antimicrobial therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial parenteral therapy in severe infections
         </strong>
         − When given, parenteral therapy is typically continued for four to six weeks before transitioning to oral therapy. (See
         <a class="local">
          'Duration of antimicrobial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Total duration of therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We suggest a prolonged total duration of antibiotic therapy (ie, 2 to 6 months for mild disease and 6 to 12 months for severe disease) in patients with classic forms of actinomycosis to prevent disease recrudescence (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Within this range, individualization of the duration depends on the initial burden of disease, the site of infection, success of surgical debridement, and the clinical and radiologic response to treatment. Shorter courses may be appropriate in cases where infection has been successfully debulked and response to treatment is rapid or in cases of nonclassic actinomycosis (eg, subcutaneous abscesses). (See
         <a class="local">
          'Duration of antimicrobial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Polymicrobial infections
         </strong>
         − Approximately 75 to 95 percent of cultures in which
         <em>
          Actinomyces
         </em>
         is isolated grow other organisms; however, antimicrobial therapy does not always need to be adjusted to target those other microorganisms. Adjusting therapy is generally warranted when organisms isolated in addition to
         <em>
          Actinomyces
         </em>
         are considered typical pathogens. In such cases, the combination of a beta lactam and a beta-lactamase inhibitor (ie,
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         ,
         <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">
          amoxicillin-clavulanate
         </a>
         ) offers the advantage of coverage against penicillin-resistant aerobic and anaerobic pathogens. (See
         <a class="local">
          'Polymicrobial infections'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical management
         </strong>
         − Surgical management (or percutaneous management) is generally not necessary for mild infections. It may be warranted in more complicated cases, such as infection in critical spaces (eg, epidural infections, intracranial abscesses, abdominal actinomycetoma, hepatic abscesses), infection complicated by massive hemoptysis, or when extensive abscesses and fistulous tracts are present. (See
         <a class="local">
          'Surgical management in select cases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring treatment response
         </strong>
         − The response to treatment should be carefully monitored, and imaging should be incorporated into follow-up to ensure appropriate resolution. (See
         <a class="local">
          'Follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Smego RA Jr, Foglia G. Actinomycosis. Clin Infect Dis 1998; 26:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilbert DN, Moellering RC Jr, Sande MA. The Sanford Guide to Antimicrobial Therapy. Antimicrobial Therapy, Inc 2001; 31:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valour F, Sénéchal A, Dupieux C, et al. Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. Infect Drug Resist 2014; 7:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin MV. The use of oral amoxycillin for the treatment of actinomycosis. A clinical and in vitro study. Br Dent J 1984; 156:252.
          </a>
         </li>
         <li class="breakAll">
          Smego RA Jr. Actinomycosis. In: Infectious Diseases, Hoeprich PD, Jordan MC, Ronald AR (Eds), Lippincott, New York 1994. p.493.
         </li>
         <li>
          <a class="nounderline abstract_t">
           PEABODY JW Jr, SEABURY JH. Actinomycosis and nocardiosis. A review of basic differences in therapy. Am J Med 1960; 28:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skoutelis A, Petrochilos J, Bassaris H. Successful treatment of thoracic actinomycosis with ceftriaxone. Clin Infect Dis 1994; 19:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonifaz A, Tirado-Sánchez A, Calderón L, et al. Treatment of cutaneous actinomycosis with amoxicillin/clavulanic acid. J Dermatolog Treat 2017; 28:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SPILSBURY BW, JOHNSTONE FR. The clinical course of actinomycotic infections: a report of 14 cases. Can J Surg 1962; 5:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen PM. Acute cervico-facial actinomycosi. Int J Oral Maxillofac Surg 1987; 156:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moturi K, Kaila V. Cervicofacial Actinomycosis and its Management. Ann Maxillofac Surg 2018; 8:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           GOLIKOV AV. [CONCENTRATION OF SOME ANTIBIOTICS IN ACTINOMYCOMA AND IN THE BLOOD OF ANIMALS WITH ACTINOMYCOSIS]. Antibiotiki 1963; 8:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin MV. Antibiotic treatment of cervicofacial actinomycosis for patients allergic to penicillin: a clinical and in vitro study. Br J Oral Maxillofac Surg 1985; 23:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lerner PI. Susceptibility of pathogenic actinomycetes to antimicrobial compounds. Antimicrob Agents Chemother 1974; 5:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmberg K, Nord CE, Dornbusch K. Antimicrobial in vitro susceptibility of actinomyces israelii and arachnia propionica. Scand J Infect Dis 1977; 9:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yew WW, Wong PC, Lee J, et al. Report of eight cases of pulmonary actinomycosis and their treatment with imipenem-cilastatin. Monaldi Arch Chest Dis 1999; 54:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith AJ, Hall V, Thakker B, Gemmell CG. Antimicrobial susceptibility testing of Actinomyces species with 12 antimicrobial agents. J Antimicrob Chemother 2005; 56:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LeCorn DW, Vertucci FJ, Rojas MF, et al. In vitro activity of amoxicillin, clindamycin, doxycycline, metronidazole, and moxifloxacin against oral Actinomyces. J Endod 2007; 33:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steininger C, Willinger B. Resistance patterns in clinical isolates of pathogenic Actinomyces species. J Antimicrob Chemother 2016; 71:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barberis C, Budia M, Palombarani S, et al. Antimicrobial susceptibility of clinical isolates of Actinomyces and related genera reveals an unusual clindamycin resistance among Actinomyces urogenitalis strains. J Glob Antimicrob Resist 2017; 8:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi J, Koh WJ, Kim TS, et al. Optimal duration of IV and oral antibiotics in the treatment of thoracic actinomycosis. Chest 2005; 128:2211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamid D, Baldauf JJ, Cuenin C, Ritter J. Treatment strategy for pelvic actinomycosis: case report and review of the literature. Eur J Obstet Gynecol Reprod Biol 2000; 89:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rolfe R, Steed LL, Salgado C, Kilby JM. Actinomyces meyeri, a Common Agent of Actinomycosis. Am J Med Sci 2016; 352:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padmanabhan A, Thomas AV. Recurrent endobronchial actinomycosis following an interventional procedure. Lung India 2017; 34:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sudhakar SS, Ross JJ. Short-term treatment of actinomycosis: two cases and a review. Clin Infect Dis 2004; 38:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moghimi M, Salentijn E, Debets-Ossenkop Y, et al. Treatment of cervicofacial actinomycosis: a report of 19 cases and review of literature. Med Oral Patol Oral Cir Bucal 2013; 18:e627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirshberg A, Tsesis I, Metzger Z, Kaplan I. Periapical actinomycosis: a clinicopathologic study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsieh MJ, Liu HP, Chang JP, Chang CH. Thoracic actinomycosis. Chest 1993; 104:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolditz M, Bickhardt J, Matthiessen W, et al. Medical management of pulmonary actinomycosis: data from 49 consecutive cases. J Antimicrob Chemother 2009; 63:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trutnovsky G, Tamussino K, Reich O. Short-term antibiotic treatment of pelvic actinomycosis. Int J Gynaecol Obstet 2008; 101:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kinnear WJ, MacFarlane JT. A survey of thoracic actinomycosis. Respir Med 1990; 84:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balis E, Kakavas S, Kompogiorgas S, et al. Presentation of pulmonary tuberculosis and actinomyces co-infection as a lung mass: a literature review and unique case report. Monaldi Arch Chest Dis 2019; 89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chicoine NH, Griffith-Linsley J, Goh J, et al. Giant Actinomyces brain abscess in an immunocompetent child: A management strategy. Surg Neurol Int 2021; 12:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chegini Z, Didehdar M, Tabaeian SP, et al. A systematic review of case reports of hepatic actinomycosis. Orphanet J Rare Dis 2021; 16:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldwag S, Abbitt PL, Watts B. Case report: percutaneous drainage of periappendiceal actinomycosis. Clin Radiol 1991; 44:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song JU, Park HY, Jeon K, et al. Treatment of thoracic actinomycosis: A retrospective analysis of 40 patients. Ann Thorac Med 2010; 5:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SR, Jung LY, Oh IJ, et al. Pulmonary actinomycosis during the first decade of 21st century: cases of 94 patients. BMC Infect Dis 2013; 13:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cintron JR, Del Pino A, Duarte B, Wood D. Abdominal actinomycosis. Dis Colon Rectum 1996; 39:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeong YJ, Suh HW, Shim HS. Cervicofacial Primary Cutaneous Actinomycosis: Surgical Treatment for Complete Remission of the Disease. J Craniofac Surg 2017; 28:e269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Ceulaer J, Tacconelli E, Vandecasteele SJ. Actinomyces osteomyelitis in bisphosphonate-related osteonecrosis of the jaw (BRONJ): the missing link? Eur J Clin Microbiol Infect Dis 2014; 33:1873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen T, Kunkel M, Springer E, et al. Actinomycosis of the jaws--histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 2007; 451:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagher R, Riaz T, Tande AJ, et al. Prosthetic Joint Infection due to Actinomyces species: A case series and review of literature. J Bone Jt Infect 2019; 4:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeffery-Smith A, Nic-Fhogartaigh C, Millar M. Is the Presence of Actinomyces spp. in Blood Culture Always Significant? J Clin Microbiol 2016; 54:1137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skuhala T, Vukelić D, Desnica B, et al. Unusual presentations of actinomycosis: a case series and literature review. J Infect Dev Ctries 2021; 15:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rueda MS, Hefter Y, Stone B, et al. A Premature Infant With Neonatal Actinomyces odontolyticus Sepsis. J Pediatric Infect Dis Soc 2021; 10:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andreani A, Rossi G, Giovannini M, Cappiello GF. Unexpected positron emission tomography-positive actinomyces-related mass of the bronchial stump. Can Respir J 2012; 19:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang S, Wolf RL, Woo JH, et al. Actinomycotic brain infection: registered diffusion, perfusion MR imaging and MR spectroscopy. Neuroradiology 2006; 48:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nozawa H, Yamada Y, Muto Y, et al. Pelvic actinomycosis presenting with a large abscess and bowel stenosis with marked response to conservative treatment: a case report. J Med Case Rep 2007; 1:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balbinot KM, Sousa NWA, Pinheiro JJV, Ribeiro ALR. Surgical debridement as a treatment strategy for cervicofacial actinomycosis-Literature review and case report. Int J Surg Case Rep 2020; 73:22.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13997 Version 14.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9636842" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Actinomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The Sanford Guide to Antimicrobial Therapy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25045274" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Actinomycosis: etiology, clinical features, diagnosis, treatment, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6584159" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The use of oral amoxycillin for the treatment of actinomycosis. A clinical and in vitro study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6584159" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The use of oral amoxycillin for the treatment of actinomycosis. A clinical and in vitro study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14431196" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Actinomycosis and nocardiosis. A review of basic differences in therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7948522" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Successful treatment of thoracic actinomycosis with ceftriaxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27151779" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Treatment of cutaneous actinomycosis with amoxicillin/clavulanic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13915786" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The clinical course of actinomycotic infections: a report of 14 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Acute cervico-facial actinomycosi
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30693266" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cervicofacial Actinomycosis and its Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14160060" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : [CONCENTRATION OF SOME ANTIBIOTICS IN ACTINOMYCOMA AND IN THE BLOOD OF ANIMALS WITH ACTINOMYCOSIS].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2933063" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Antibiotic treatment of cervicofacial actinomycosis for patients allergic to penicillin: a clinical and in vitro study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4840438" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Susceptibility of pathogenic actinomycetes to antimicrobial compounds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/841278" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Antimicrobial in vitro susceptibility of actinomyces israelii and arachnia propionica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10394825" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Report of eight cases of pulmonary actinomycosis and their treatment with imipenem-cilastatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15972310" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Antimicrobial susceptibility testing of Actinomyces species with 12 antimicrobial agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17437871" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : In vitro activity of amoxicillin, clindamycin, doxycycline, metronidazole, and moxifloxacin against oral Actinomyces.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26538502" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Resistance patterns in clinical isolates of pathogenic Actinomyces species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28109846" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Antimicrobial susceptibility of clinical isolates of Actinomyces and related genera reveals an unusual clindamycin resistance among Actinomyces urogenitalis strains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16236876" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Optimal duration of IV and oral antibiotics in the treatment of thoracic actinomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10725583" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Treatment strategy for pelvic actinomycosis: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27432035" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Actinomyces meyeri, a Common Agent of Actinomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28360473" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Recurrent endobronchial actinomycosis following an interventional procedure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14727221" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Short-term treatment of actinomycosis: two cases and a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23722146" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Treatment of cervicofacial actinomycosis: a report of 19 cases and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12738954" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Periapical actinomycosis: a clinicopathologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8339619" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Thoracic actinomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19218569" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Medical management of pulmonary actinomycosis: data from 49 consecutive cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18164011" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Short-term antibiotic treatment of pelvic actinomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2371423" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A survey of thoracic actinomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31850696" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Presentation of pulmonary tuberculosis and actinomyces co-infection as a lung mass: a literature review and unique case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34345466" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Giant Actinomyces brain abscess in an immunocompetent child: A management strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33931097" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A systematic review of case reports of hepatic actinomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1773565" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Case report: percutaneous drainage of periappendiceal actinomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20582172" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Treatment of thoracic actinomycosis: A retrospective analysis of 40 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23672372" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Pulmonary actinomycosis during the first decade of 21st century: cases of 94 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8601346" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Abdominal actinomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28468217" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cervicofacial Primary Cutaneous Actinomycosis: Surgical Treatment for Complete Remission of the Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24880820" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Actinomyces osteomyelitis in bisphosphonate-related osteonecrosis of the jaw (BRONJ): the missing link?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17952459" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Actinomycosis of the jaws--histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31555503" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Prosthetic Joint Infection due to Actinomyces species: A case series and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26818678" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Is the Presence of Actinomyces spp. in Blood Culture Always Significant?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34242202" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Unusual presentations of actinomycosis: a case series and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33136166" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A Premature Infant With Neonatal Actinomyces odontolyticus Sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22536574" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Unexpected positron emission tomography-positive actinomyces-related mass of the bronchial stump.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16614822" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Actinomycotic brain infection: registered diffusion, perfusion MR imaging and MR spectroscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18031582" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Pelvic actinomycosis presenting with a large abscess and bowel stenosis with marked response to conservative treatment: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32629216" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Surgical debridement as a treatment strategy for cervicofacial actinomycosis-Literature review and case report.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
